PDCD1 and head and neck squamous cell carcinoma: To date, for the treatment of recurrent and metastatic HNSCC, none of the currently approved agents (cetuximab targeting EGFR [46], pembrolizumab [47], and nivolumab [48] which targets programmed cell death protein-1 (PD-1)) are biomarker-based [49].